NLS Global report

AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited.

The EU member states have agreed on a compromise for pharmaceutical legislation, which means, among other things, that the data protection period will remain unchanged at eight years.

A new strategic collaboration between life science clusters from Northern Europe and the UK’s National Institute for Health and Care Research (NIHR) is set to open new pathways for companies to engage with the UK’s healthcare and research ecosystem.

With the agreement, the Novo Nordisk Foundation expands its existing collaboration with WHO, committing to a granting frame of up to DKK 380 million over the next four years.

The companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types.

Opdivo is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union.